Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 11/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025899 | 1.00 | TSHR (0.34) | TSHRFFAR2POLBHTTCNR2 | |
| SCHEMBL13822083 | 0.93 | TSHR (0.33) | TSHRPOLBHTTCNR2NR4A1 | |
| SCHEMBL10025903 | 0.92 | FFAR2 (0.33) | TSHRFFAR2POLBHTTADRA1A | |
| SCHEMBL10025902 | 0.92 | FFAR2 (0.33) | TSHRFFAR2POLBHTTADRA1A | |
| SCHEMBL10025912 | 0.92 | FFAR2 (0.33) | TSHRFFAR2POLBHTTADRA1A | |
| SCHEMBL10025900 | 0.90 | PDE5A (0.39) | TSHRFFAR2POLB | |
| SCHEMBL10025901 | 0.90 | PDE5A (0.39) | TSHRFFAR2POLB | |
| SCHEMBL10025913 | 0.90 | PDE5A (0.39) | TSHRFFAR2POLB | |
| SCHEMBL10025911 | 0.83 | PDE5A (0.36) | TSHR | |
| SCHEMBL10025893 | 0.81 | P2RX7 (0.38) | TSHRPOLBHTTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124616-B2 | Bicyclic PPAT inhibitors as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-28 | — | — | US | disclosed |
| US-8124616-B2 | Bicyclic PPAT inhibitors as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-28 | — | — | US | disclosed |
| US-20090203730-A1 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | MAXTHERA INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203730-A1 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | MAXTHERA INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203730-A1 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | APRT, PPA1, GNPAT | TSHR 4249/4885FFAR2 3507/4885POLB 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.